Plain-English translation of NCT05088798 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tests a special imaging scan called 18F-DOPA PET/MRI that helps doctors find small, hard-to-detect insulin-producing tumors in the pancreas. The scan works by using a tracer that lights up insulin-producing cells, making them visible on the imaging pictures. This test is designed to help doctors confirm where these tumors are located before surgery, so they can remove them safely while preserving as much healthy pancreas as possible.
Some patients with severe low blood sugar have insulin-producing tumors that are too small to find with standard imaging like CT or ultrasound. Having a better way to locate these tiny tumors before surgery is critical, because surgery is often the only treatment option and doctors need to know exactly where to operate.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital or imaging center to receive the 18F-DOPA PET/MRI scan. A small amount of tracer (a radioactive substance) is given to you, and then you lie still inside the scanning machine while it takes detailed pictures of your pancreas. The scan itself typically takes 30–60 minutes. This imaging test will help your surgical team locate your tumor before any operation.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Washington University School of Medicine
Collaborators
St. Louis Children's Hospital
Enrollment target
~100 participants
Started
September 2020
Primary completion
January 2030
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pamela S Stone, RN
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.